Skip to main content
. 2017 Aug 4;7:7328. doi: 10.1038/s41598-017-06767-y

Table 1.

Participants’ characteristics.

1st cohort 2nd cohort
Control Parkinson’s disease P-valuea Control Parkinson’s disease P-valuea
Number 32 109 45 145
Gender (Male:Female) 14:18 59:50 0.473b 23:22 70:75 0.740b
Age [years], Mean (SD) 62.9 (12.4) 67.3 (9.99) 0.0566 63.8 (15.3) 67.5 (10.2) 0.392
Duration [years], Mean (SD) 6.48 (5.64) 7.04 (5.61)
H&Y stage, (each case number) I (26), II (52), III (21), IV (9), V (1) I (41), II (60), III (35), IV (8), V (1)
H&Y stage, Mean (SD) 2.15 (0.91) 2.09 (0.897)
UPDRS III, Mean (SD) 13.9 (10.5) 14.8 (9.84)
MMSE, Mean (SD) 28.5 (1.74) 28.9 (2.09) 27.8 (3.14) <0.0001
BMI [kg/m2], Mean (SD) 24.1 (3.88) 21.9 (2.97) 0.0081 23.2 (3.59) 22.4 (3.29) 0.0867
CK [U/ml], Mean (SD) 118 (47.8) 134 (91.7) 0.750
Aldolase [IU/l], Mean (SD) 3.64 (1.54) 3.98 (1.25) 0.0142
HbA1c [%], Mean (SD) 5.70 (0.378) 5.74 (0.396) 0.570
NEFA [mEq/l], Mean (SD) 571 (200) 613 (257) 0.420

Abbreviations: SD = standard deviation; H&Y stage = Hoehn and Yahr stage; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini Mental State Examination; BMI = Body Mass Index; CK = creatine kinase; ALD = aldolase; HbA1c = hemoglobin A1c; NEFA = non-esterified fatty acid.

a P-value obtained by analysis of covariance between controls and PD.

b P-value obtained by chi-squared test.